Description

AbbVie Acquisition Move: The $10.9 Billion Immunology Gamble Explained!

AbbVie Acquisition Move: The $10.9 Billion Immunology Gamble Explained AbbVie has moved quickly to deepen its immunology franchise, completing its $10.9 billion acquisition of Apogee Therapeutics on September 3, 2026, after first announcing the transaction during the second quarter. The purchase is AbbVie’s largest bolt-on deal since 2019 and adds a portfolio of long-acting biologics targeting atopic dermatitis, respiratory conditions, and other immune-mediated diseases. Management has framed Apogee as a strategic addition to a pipeline already anchored by Skyrizi and Rinvoq, with the aim of extending growth into the 2030s and beyond. The timing also matters financially: AbbVie expects the deal to reduce adjusted diluted EPS by $0.14 in 2026 and about $0.46 in 2027, with accretion beginning in 2032. Even after incorporating the near-term dilution, AbbVie reaffirmed 2026 adjusted EPS guidance of $13.87 to $14.